In the last few years, there has been an increase in research around using psychedelic drugs, like LSD and magic mushrooms, as treatments for mental health conditions. And recently, two Canadian companies working in the sphere have gotten a special designation from a big U.S. regulator that could fast-track the development and review of their drugs.
Sean Silcoff is a journalist with The Globe’s Report on Business. He has been looking at recent developments in these companies and how that fits into the bigger picture of investor excitement around these drugs.
Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com
The controversy over lowering the age of breast cancer screening
Inside the Israel-Gaza war zone
The influence of the U.S. on the Israel-Hamas war
The Decibel presents: In Her Defence
The problems with how government contracts get outsourced
War erupts between Israel and Hamas
How Canadian-made PAW Patrol took over kids’ entertainment
A dropped case and the slow reckoning of the Canadian military
Catch and release: the revolving door of violent repeat offenders
How a group of Buddhist monks bought up a chunk of PEI
Ukrainian refugees fled to Poland. Now thousands are leaving
Can a 4 billion year-old asteroid reveal the origins of life?
A Dollarama executive, a luxury home and a World Heritage site
Why it’s so hard to bring food prices down
Will 3.45 million new homes solve Canada’s housing crisis?
What’s behind the delays in Canada’s courts?
Introducing: In Her Defence, a new true crime podcast
The view from India after allegations of killing in Canada
Your Ontario Greenbelt questions, answered
Trudeau accuses India of involvement in Canadian’s murder
Create your
podcast in
minutes
It is Free
Front Burner
At Issue
The Daily
Today, Explained
Morning Wire